Oncternal Therapeutics Inc Key Opinion Leader (KOL) Webinar on Cirmtuzumab for Treating Patients with Mantle Cell Transcript
Good afternoon, and welcome to the Oncternal Therapeutics KOL Call on Cirmtuzumab for the Treatment of Mantle Cell Lymphoma. (Operator Instructions) As a reminder, this conference is being recorded, and a replay will be made available on the Oncternal website following the event.
I would now like to turn the call over to your host, Dr. James Breitmeyer, Chief Executive Officer at Oncternal Therapeutics. Please go ahead, Doctor.
Thank you, Sarah, and welcome, everybody. Thanks for joining us on this call to discuss the current therapeutic landscape for mantle cell lymphoma and the role that Oncternal's drug cirmtuzumab may play as a potential new treatment in that disease. The primary goal of this call is for you to hear from Dr. Michael Wang, a true key opinion leader in the field of hematology, and more specifically, in mantle cell lymphoma.
Next slide, please. As you can see from this agenda, after my opening remarks, I'll turn it over to Dr. Wang to discuss
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |